Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Gland Pharma has informed that the ESOP Compensation Committee of the Board of Directors of the Company in its meeting held on June 02, 2026, has allotted 2,03,259 Equity shares of Re 1 each of the Company, fully paid up, to 77 employee(s) on exercise of their Stock Options pursuant to Gland Pharma Employee Stock Options Scheme, 2025. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 164,959,682 comprising 164,959,682 Equity shares of face value Re 1 each. Further, it has enclosed the details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
The above information is a part of company’s filings submitted to BSE.
